This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kuba, K. Articles by Nakamura, T. Search for Related Content PubMed PubMed Citation Articles by Kuba, K. Articles by Nakamura, T.

HGF/NK4, a Four-Kringle Antagonist of Hepatocyte Growth Factor, Is an Angiogenesis Inhibitor that Suppresses Tumor Growth and Metastasis in Mice¹

Division of Biochemistry, Department of Oncology, Biomedical Research Center, Osaka University Medical School, Suita, Osaka 565-0871, Japan [K. K., K. M., T. N.]; Department of Surgery 1, Kyushu University Faculty of Medicine, Maidashi, Fukuoka 812-8582, Japan [K. K., K. D., M. T.]; and Department of Surgery 1, Fukuoka University School of Medicine, Nanakuma, Fukuoka 814-0180, Japan [H. S.]

We reported that NK4, composed of the N-terminal hairpin and subsequent four kringle domains of hepatocyte growth factor (HGF), acts as the competitive antagonist for HGF. We now provide the first evidence that NK4 inhibits tumor growth and metastasis as an angiogenesis inhibitor as well as an HGF antagonist. Administration of NK4 suppressed primary tumor growth and lung metastasis of Lewis lung carcinoma and Jyg-MC(A) mammary carcinoma s.c. implanted into mice, although neither HGF nor NK4 affected proliferation and survival of these tumor cells in vitro. NK4 treatment resulted in a remarkable decrease in microvessel density and an increase of apoptotic tumor cells in primary tumors, which suggests that the inhibition of primary tumor growth by NK4 may be achieved by suppression of tumor angiogenesis. In vivo, NK4 inhibited angiogenesis in chick chorioallantoic membranes and in rabbit corneal neovascularization induced by basic fibroblast growth factor (bFGF). In vitro, NK4 inhibited growth and migration of human microvascular endothelial cells induced by bFGF and vascular endothelial growth factor (VEGF) as well as by HGF. HGF and VEGF activated the Met/HGF receptor and the KDR/VEGF receptor, respectively, whereas NK4 inhibited HGF-induced Met tyrosine phosphorylation but not VEGF-induced KDR phosphorylation. NK4 inhibited HGF-induced ERK1/2 (p44/42 mitogen-activated protein kinase) activation, but allowed for bFGF- and VEGF-induced ERK1/2 activation. These results indicate that NK4 is an angiogenesis inhibitor as well as an HGF antagonist, and that the antiangiogenic action of NK4 is independent of its activity as HGF antagonist. The bifunctional properties of NK4 to act as an angiogenesis inhibitor and as an HGF antagonist raises the possibility that NK4 may prove therapeutic for cancer patients.

This article has been cited by other articles:

				K. Sakai, T. Nakamura, K. Matsumoto, and T. Nakamura Angioinhibitory Action of NK4 Involves Impaired Extracellular Assembly of Fibronectin Mediated by Perlecan-NK4 Association J. Biol. Chem., August 14, 2009; 284(33): 22491 - 22499. [Abstract] [Full Text] [PDF]

				E. G. SKOLDENBERG, A. LARSSON, A. JAKOBSON, F. HEDBORG, P. KOGNER, R. H. CHRISTOFFERSON, and F. AZARBAYJANI The Angiogenic Growth Factors HGF and VEGF in Serum and Plasma from Neuroblastoma Patients Anticancer Res, August 1, 2009; 29(8): 3311 - 3319. [Abstract] [Full Text] [PDF]

				L. Toschi and P. A. Janne Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer Clin. Cancer Res., October 1, 2008; 14(19): 5941 - 5946. [Abstract] [Full Text] [PDF]

				B. Nie, Z. Shen, J.-B. Wen, O. G.-W. Wong, W. D. Hsueh, L.-F. Huo, H.-F. Kung, B. Jiang, and M. C.M. Lin AAV-HGFK1 and Ad-p53 cocktail therapy prolongs survival of mice with colon cancer Mol. Cancer Ther., September 1, 2008; 7(9): 2855 - 2865. [Abstract] [Full Text] [PDF]

				H.-K. Kim, D.-S. Oh, S.-B. Lee, J.-M. Ha, and Y. A. Joe Antimigratory effect of TK1-2 is mediated in part by interfering with integrin {alpha}2{beta}1 Mol. Cancer Ther., July 1, 2008; 7(7): 2133 - 2141. [Abstract] [Full Text] [PDF]

				Z. Shen, Z. F. Yang, Y. Gao, J. C. Li, H. X. Chen, C. C. Liu, R. T.P. Poon, S. T. Fan, J. M. Luk, K. H. Sze, et al. The Kringle 1 Domain of Hepatocyte Growth Factor Has Antiangiogenic and Antitumor Cell Effects on Hepatocellular Carcinoma Cancer Res., January 15, 2008; 68(2): 404 - 414. [Abstract] [Full Text] [PDF]

				W. Du, Y. Hattori, T. Yamada, K. Matsumoto, T. Nakamura, M. Sagawa, T. Otsuki, T. Niikura, T. Nukiwa, and Y. Ikeda NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor Blood, April 1, 2007; 109(7): 3042 - 3049. [Abstract] [Full Text] [PDF]

				R. Abounader and J. Laterra Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis Neuro-oncol, October 1, 2005; 7(4): 436 - 451. [Abstract] [PDF]

				T.-L. Cheng, M.-Y. Chang, S.-Y. Huang, C.-C. Sheu, E.-L. Kao, Y.-J. Cheng, and I.-W. Chong Overexpression of Circulating c-Met Messenger RNA Is Significantly Correlated With Nodal Stage and Early Recurrence in Non-Small Cell Lung Cancer Chest, September 1, 2005; 128(3): 1453 - 1460. [Abstract] [Full Text] [PDF]

				V. A. Carroll, L. L. Nikitenko, R. Bicknell, and A. L. Harris Antiangiogenic Activity of a Domain Deletion Mutant of Tissue Plasminogen Activator Containing Kringle 2 Arterioscler Thromb Vasc Biol, April 1, 2005; 25(4): 736 - 741. [Abstract] [Full Text] [PDF]

				N. Sato, N. Maehara, and M. Goggins Gene Expression Profiling of Tumor-Stromal Interactions between Pancreatic Cancer Cells and Stromal Fibroblasts Cancer Res., October 1, 2004; 64(19): 6950 - 6956. [Abstract] [Full Text] [PDF]

				M. Maemondo, Y. Saijo, K. Narumi, T. Kikuchi, K. Usui, R. Tazawa, K. Matsumoto, T. Nakamura, K. Sasaki, M. Takahashi, et al. Gene Therapy with Secretory Leukoprotease Inhibitor Promoter-Controlled Replication-Competent Adenovirus for Non-Small Cell Lung Cancer Cancer Res., July 1, 2004; 64(13): 4611 - 4620. [Abstract] [Full Text] [PDF]

				N. Nakano, S. Higashiyama, H. Ohmoto, H. Ishiguro, N. Taniguchi, and Y. Wada The N-terminal Region of NTAK/Neuregulin-2 Isoforms Has an Inhibitory Activity on Angiogenesis J. Biol. Chem., March 19, 2004; 279(12): 11465 - 11470. [Abstract] [Full Text] [PDF]

				T. Goi, M. Fujioka, Y. Satoh, S. Tabata, K. Koneri, H. Nagano, Y. Hirono, K. Katayama, K. Hirose, and A. Yamaguchi Angiogenesis and Tumor Proliferation/Metastasis of Human Colorectal Cancer Cell Line SW620 Transfected with Endocrine Glands-Derived-Vascular Endothelial Growth Factor, As a New Angiogenic Factor Cancer Res., March 15, 2004; 64(6): 1906 - 1910. [Abstract] [Full Text] [PDF]

				S. Yoshida, T. Harada, M. Mitsunari, T. Iwabe, Y. Sakamoto, S. Tsukihara, Y. Iba, S. Horie, and N. Terakawa Hepatocyte Growth Factor/Met System Promotes Endometrial and Endometriotic Stromal Cell Invasion via Autocrine and Paracrine Pathways J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 823 - 832. [Abstract] [Full Text] [PDF]

				M. Krix, F. Kiessling, S. Vosseler, N. Farhan, M. M. Mueller, P. Bohlen, N. E. Fusenig, and S. Delorme Sensitive Noninvasive Monitoring of Tumor Perfusion during Antiangiogenic Therapy by Intermittent Bolus-Contrast Power Doppler Sonography Cancer Res., December 1, 2003; 63(23): 8264 - 8270. [Abstract] [Full Text] [PDF]

				S. J. Kim, M. Johnson, K. Koterba, M. H. Herynk, H. Uehara, and G. E. Gallick Reduced c-Met Expression by an Adenovirus Expressing a c-Met Ribozyme Inhibits Tumorigenic Growth and Lymph Node Metastases of PC3-LN4 Prostate Tumor Cells in an Orthotopic Nude Mouse Model Clin. Cancer Res., November 1, 2003; 9(14): 5161 - 5170. [Abstract] [Full Text] [PDF]

				X. Wang, P. Le, C. Liang, J. Chan, D. Kiewlich, T. Miller, D. Harris, L. Sun, A. Rice, S. Vasile, et al. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion Mol. Cancer Ther., November 1, 2003; 2(11): 1085 - 1092. [Abstract] [Full Text] [PDF]

				Y.-W. Zhang, Y. Su, O. V. Volpert, and G. F. V. Woude Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation PNAS, October 28, 2003; 100(22): 12718 - 12723. [Abstract] [Full Text] [PDF]

				M. A. Brockmann, A. Papadimitriou, M. Brandt, R. Fillbrandt, M. Westphal, and K. Lamszus Inhibition of Intracerebral Glioblastoma Growth by Local Treatment with the Scatter Factor/Hepatocyte Growth Factor-Antagonist NK4 Clin. Cancer Res., October 1, 2003; 9(12): 4578 - 4585. [Abstract] [Full Text] [PDF]

				T. Merkulova-Rainon, P. England, S. Ding, C. Demerens, and G. Tobelem The N-terminal Domain of Hepatocyte Growth Factor Inhibits the Angiogenic Behavior of Endothelial Cells Independently from Binding to the c-met Receptor J. Biol. Chem., September 26, 2003; 278(39): 37400 - 37408. [Abstract] [Full Text] [PDF]

				T. Manabe, K. Mizumoto, E. Nagai, K. Matsumoto, T. Nakamura, T. Nukiwa, M. Tanaka, and T. Matsuda Cell-based Protein Delivery System for the Inhibition of the Growth of Pancreatic Cancer: NK4 Gene-transduced Oral Mucosal Epithelial Cell Sheet Clin. Cancer Res., August 1, 2003; 9(8): 3158 - 3166. [Abstract] [Full Text] [PDF]

				M. Numasaki, J.-i. Fukushi, M. Ono, S. K. Narula, P. J. Zavodny, T. Kudo, P. D. Robbins, H. Tahara, and M. T. Lotze Interleukin-17 promotes angiogenesis and tumor growth Blood, April 1, 2003; 101(7): 2620 - 2627. [Abstract] [Full Text] [PDF]

				K. S. Kim, Y.-K. Hong, Y. A. Joe, Y. Lee, J.-Y. Shin, H.-E. Park, I.-H. Lee, S.-Y. Lee, D.-K. Kang, S.-I. Chang, et al. Anti-angiogenic Activity of the Recombinant Kringle Domain of Urokinase and Its Specific Entry into Endothelial Cells J. Biol. Chem., March 21, 2003; 278(13): 11449 - 11456. [Abstract] [Full Text] [PDF]

				N. Wajih and D. C. Sane Angiostatin selectively inhibits signaling by hepatocyte growth factor in endothelial and smooth muscle cells Blood, March 1, 2003; 101(5): 1857 - 1863. [Abstract] [Full Text] [PDF]

				T. Kikuchi, M. Maemondo, K. Narumi, K. Matsumoto, T. Nakamura, and T. Nukiwa Tumor suppression induced by intratumor administration of adenovirus vector expressing NK4, a 4-kringle antagonist of hepatocyte growth factor, and naive dendritic cells Blood, December 1, 2002; 100(12): 3950 - 3959. [Abstract] [Full Text] [PDF]

				M. Saimura, E. Nagai, K. Mizumoto, N. Maehara, Y. A. Minamishima, M. Katano, K. Matsumoto, T. Nakamura, and M. Tanaka Tumor Suppression through Angiogenesis Inhibition by SUIT-2 Pancreatic Cancer Cells Genetically Engineered to Secrete NK4 Clin. Cancer Res., October 1, 2002; 8(10): 3243 - 3249. [Abstract] [Full Text] [PDF]

				Y. To, M. Dohi, K. Matsumoto, R. Tanaka, A. Sato, K. Nakagome, T. Nakamura, and K. Yamamoto A Two-way Interaction between Hepatocyte Growth Factor and Interleukin-6 in Tissue Invasion of Lung Cancer Cell Line Am. J. Respir. Cell Mol. Biol., August 1, 2002; 27(2): 220 - 226. [Abstract] [Full Text] [PDF]

				Y. Saijo, M. Tanaka, M. Miki, K. Usui, T. Suzuki, M. Maemondo, X. Hong, R. Tazawa, T. Kikuchi, K. Matsushima, et al. Proinflammatory Cytokine IL-1{beta} Promotes Tumor Growth of Lewis Lung Carcinoma by Induction of Angiogenic Factors: In Vivo Analysis of Tumor-Stromal Interaction J. Immunol., July 1, 2002; 169(1): 469 - 475. [Abstract] [Full Text] [PDF]

				D. Tomioka, N. Maehara, K. Kuba, K. Mizumoto, M. Tanaka, K. Matsumoto, and T. Nakamura Inhibition of Growth, Invasion, and Metastasis of Human Pancreatic Carcinoma Cells by NK4 in an Orthotopic Mouse Model Cancer Res., October 1, 2001; 61(20): 7518 - 7524. [Abstract] [Full Text] [PDF]

				K. Matsumoto, H. Yoshitomi, J. Rossant, and K. S. Zaret Liver Organogenesis Promoted by Endothelial Cells Prior to Vascular Function Science, October 19, 2001; 294(5542): 559 - 563. [Abstract] [Full Text] [PDF]